Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

...

Nutra Pharma Corp.

(Public, OTC:NPHC)

StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when

...

Alexion: One-Drug Wonder Continues - How Long Can This Be Sustained? Soliris sales continues to grow in 1Q09Late last week, Alexion Pharmaceuticals, Inc. (ALXN) reported first quarter 2009 financial results. Soliris sales were in line with our expectation of $81.3 million -- up 78.1% y-o-y and 5% sequentially.Due to strong Soliris sales, Alexion has been enjoying profitability since the second quarter last year. In 1Q09, adjusted net income was $14.6 million, with diluted earnings per share (EPS) of $0.16. Excluding share-based expenses, Alexion achieved a net income of $22.5 million or EPS of $0.25 in 1Q09. First quarter net income and EPS were less than our estimate of $17.6 million and $0.19 per share due to higher R&D and SG&A expenses. Soliris (eculizumab) is a humanized monoclonal antibody complement inhibitor, which blocks cleavage of the C5 component of the complement ...

Amarin Corporation (NASDAQ: AMRN) is a neuroscience company focused on the research, development and commercialization of novel drugs that address unmet patient needs. Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases.

Amarin continues to focus their efforts on employing a novel, proprietary platform based on knowledge of the chemical nature and highly vascular environment of the brain to develop pharmaceuticals in the area of neurology. The company’s unique technology of lipophilic drugs is predominately fat-soluble, which helps facilitate transportation across the blood-brain barrier. This is a crucial component since the majority of drugs that are currently available to treat neurological and psychiatric disorders have mechanisms of action targeting receptors of the brain or neurotransmitters located in the brain’s makeup.

The company has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of

...